On this page
⚠ Educational content only Not medical or genetic advice. Speak with a healthcare provider or genetic counsellor before acting on anything here.

UPB1

beta-ureidopropionase 1

Chromosome 22q11.23 Autosomal recessive HGNC:16297 Tier C
UPB1 22q11.23 p arm q arm 22

UPB1 is located on the long (q) arm of chromosome 22, at band 22q11.23. Arm ratio per GRCh38 - banding schematic.

Explore chromosome 22 in the library →

Available at Jeen Health

Clinical tests that include this

Overview

The UPB1 gene, located on chromosome 22, provides instructions for making the beta-ureidopropionase enzyme. This protein plays a crucial role in the body's recycling system for pyrimidines, the chemical building blocks of DNA and RNA. When cells break down old or damaged genetic material, pyrimidines must be degraded through a multi-step pathway. Beta-ureidopropionase performs the final conversion in this sequence, transforming intermediate breakdown products into simpler molecules.

Pathogenic changes in both copies of UPB1 lead to beta-ureidopropionase deficiency, a rare inherited metabolic disorder. Individuals with this condition accumulate pyrimidine breakdown intermediates in their urine and may experience neurological problems ranging from mild learning difficulties to severe developmental delay and seizures. The gene follows an autosomal recessive inheritance pattern, meaning affected individuals inherit one non-working copy from each parent.

What the gene does

Beta-ureidopropionase catalyses the terminal step in the pyrimidine degradation pathway, converting two specific substrates into physiologically important products. The enzyme breaks down N-carbamyl-beta-alanine into beta-alanine, ammonia, and carbon dioxide, whilst also converting N-carbamyl-beta-aminoisobutyric acid into beta-aminoisobutyric acid. These products appear to have roles beyond simple waste elimination.

Beta-alanine is thought to participate in communication between nerve cells and may help regulate dopamine, a neurotransmitter critical for movement, motivation, and cognition. Beta-aminoisobutyric acid influences production of leptin, a protein that research suggests can protect neurons from damage caused by inflammation, toxic substances, and metabolic stress. By generating these molecules, beta-ureidopropionase links nucleotide turnover to nervous system homeostasis, explaining why enzyme deficiency often manifests with neurological features rather than purely metabolic disturbance.

Video: Genetics 101

Chromosome location

UPB1 is located on the long arm of chromosome 22 at position 22q11.23. This chromosomal region contains numerous genes and has been associated with various genomic disorders. The gene encodes a protein of 384 amino acids, though specific information regarding exon number and transcript variants has not been extensively characterised in public databases.

Protein structure

The beta-ureidopropionase protein contains a CN hydrolase domain extending from amino acid 72 to 344, which encompasses the majority of the mature enzyme. This catalytic domain belongs to the carbon-nitrogen hydrolase superfamily, a group of enzymes that cleave carbon-nitrogen bonds in various substrates. The domain architecture reflects the protein's specialised function in breaking down the carbon-nitrogen linkages present in N-carbamyl compounds generated during pyrimidine catabolism. Structural features outside the core hydrolase domain have not been extensively characterised in published literature.

Domain map · 384 amino acids
CN hydrolase (72-344)CN hydrolase72-3441~192384
Domain - independent functional unit
🧬 Explore 3D structure on AlphaFold
UniProt:Q9UBR1Length:384 aaStructure:AlphaFold

Key variants

At least 16 different pathogenic variants in UPB1 have been identified in individuals with beta-ureidopropionase deficiency. These genetic changes typically reduce or eliminate enzyme activity, preventing normal breakdown of pyrimidine metabolites. The resulting accumulation of N-carbamyl-beta-alanine and N-carbamyl-beta-aminoisobutyric acid in urine serves as a biochemical marker for the condition. Variant severity may influence the degree of neurological involvement, though genotype-phenotype correlations remain incompletely understood.

The table below shows the top 10 pathogenic or likely-pathogenic variants currently classified in ClinVar for UPB1.
View all on ClinVar →

Sample of pathogenic variants

10 pathogenic / likely-pathogenic variants from ClinVar, ranked by review status (expert-panel-reviewed first). This is a sample; recurrent founder variants in a specific population may not appear here - see the full ClinVar listing via the link above.

Variant (HGVS) Protein change Classification Evidence Associated condition
c.352C>T
single nucleotide variant
p.Gln118Ter Pathogenic ★★☆☆ Deficiency of beta-ureidopropionase
c.873+1G>A
single nucleotide variant
- Pathogenic/Likely pathogenic ★★☆☆ Deficiency of beta-ureidopropionase
c.917-1G>A
single nucleotide variant
- Pathogenic/Likely pathogenic ★★☆☆ UPB1-related disorder
g.(?_24891299)_(24898182_24906716)del
Deletion
- Pathogenic ★☆☆☆ Deficiency of beta-ureidopropionase
c.254del
Deletion
p.Ala85fs Pathogenic ★☆☆☆ Deficiency of beta-ureidopropionase
c.641del
Deletion
p.Gly214fs Pathogenic ★☆☆☆ Inborn genetic diseases
c.670C>T
single nucleotide variant
p.Gln224Ter Pathogenic ★☆☆☆ Deficiency of beta-ureidopropionase
c.874G>T
single nucleotide variant
p.Glu292Ter Pathogenic ★☆☆☆ not provided
c.887_890del
Deletion
p.Asn296fs Pathogenic ★☆☆☆ not provided
c.952_964del
Deletion
p.Tyr318fs Pathogenic ★☆☆☆ not provided

Evidence stars indicate ClinVar review status. Individual variant interpretation should always be performed by a qualified clinical laboratory - many variants remain classified as Variants of Uncertain Significance (VUS) pending more research.

Associated conditions

Pathogenic variants in both copies of UPB1 cause beta-ureidopropionase deficiency, a rare autosomal recessive metabolic disorder. The hallmark biochemical finding is excessive urinary excretion of pyrimidine breakdown intermediates. Clinical manifestations vary considerably among affected individuals. Some people remain largely asymptomatic and are identified only through metabolic screening, whilst others develop significant neurological problems including seizures, developmental delay, and intellectual disability ranging from mild to severe. The factors determining this clinical variability are not fully established, though they may relate to specific variants, residual enzyme activity, and genetic modifiers.

No condition pages are linked to this gene yet. This does not mean it has no associated conditions.

Inheritance pattern

Conditions caused by pathogenic UPB1 variants typically follow autosomal recessive inheritance.

♀ Carrier parent 1 altered copy ♂ Carrier parent 1 altered copy Affected Carrier Carrier Unaffected Affected Carrier Unaffected Circles = females · Squares = males

When both parents are carriers, each child has a 25% chance of being affected, 50% of being a carrier, and 25% of being unaffected.

Carrier frequency by population How common is heterozygous UPB1 carrier status across ancestry groups?

UK clinical status

UPB1 appears on the NHS Genomic Medicine Service gene panel for likely inborn error of metabolism, designated with green classification status. This inclusion reflects recognition that beta-ureidopropionase deficiency, whilst rare, represents a diagnosable inherited metabolic condition. The green rating indicates strong evidence supporting the gene-disease relationship, facilitating appropriate genetic testing for individuals presenting with unexplained neurological features and characteristic biochemical findings.

Frequently asked questions

What is beta-ureidopropionase deficiency?

Beta-ureidopropionase deficiency is a rare autosomal recessive disorder caused by pathogenic variants in both copies of the UPB1 gene. Affected individuals cannot properly break down pyrimidine building blocks, leading to accumulation of metabolic intermediates in urine and potentially causing neurological problems ranging from mild learning difficulties to severe developmental delay and seizures.

How is UPB1 inherited?

UPB1 follows an autosomal recessive inheritance pattern. This means an individual must inherit one non-working copy of the gene from each parent to develop beta-ureidopropionase deficiency. Parents who each carry one pathogenic variant typically have no symptoms but have a 25% chance with each pregnancy of having an affected child.

Why does UPB1 deficiency affect the nervous system?

Beta-ureidopropionase normally produces beta-alanine and beta-aminoisobutyric acid, molecules thought to support nerve cell communication and protect brain cells from damage. When the enzyme is deficient, reduced levels of these products combined with accumulation of breakdown intermediates may disrupt normal neurological function, though the precise mechanisms remain under investigation.

References

  1. Nakajima Y, Meijer J, Dobritzsch D. Clinical, biochemical and molecular analysis of 13 Japanese patients with β-ureidopropionase deficiency demonstrates high prevalence of the c.977G > A (p.R326Q) mutation [corrected]. Journal of inherited metabolic disease. 2014. PMID: 24526388
  2. van Kuilenburg AB, Dobritzsch D, Meijer J. ß-ureidopropionase deficiency: phenotype, genotype and protein structural consequences in 16 patients. Biochimica et biophysica acta. 2012. PMID: 22525402
  3. van Kuilenburg AB, Meinsma R, Assman B. Genetic analysis of the first 4 patients with beta-ureidopropionase deficiency. Nucleosides, nucleotides & nucleic acids. 2006. PMID: 17065070
  4. van Kuilenburg AB, Meinsma R, Beke E. beta-Ureidopropionase deficiency: an inborn error of pyrimidine degradation associated with neurological abnormalities. Human molecular genetics. 2004. PMID: 15385443
Educational content. This page is not medical or genetic advice, is not individually reviewed by a clinician for each reader, and should not replace a consultation with a qualified healthcare professional or genetic counsellor. If you are considering genetic testing or acting on a test result, book a consultation.
Data sources Last updated 17 April 2026. Content compiled from HGNC · MedlinePlus Genetics · ClinGen · Genomics England PanelApp · NHS National Genomic Test Directory · ClinVar · UniProt · AlphaFold .